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By aesthetic and monetary criteria, 
whole-animal screening with ro\\ 
upon row of smelly mouse cages is no 
match for in vitro screening. Receptor- 
binding assays, enzyme-inhibition 
assal;s, and all of their cousins, can be 
done in sin& wells of a multiwell 
plate. with cl-cqthing dispensed 
through robot-controlled fluidic 
systems. NOM NemaPharm, Inc. 
(Cambridge. hlassachusctts) has 
transformed the \+hole-animal screen 
into the same high-throughput 
format. “NemaPharm is establishing 
surrogates for human diseases, and 
then devising selections for drugs 
against those diseases,” says Carl 
Johnson, a founder and \.icc President 
of Research at NcmaPharm. ‘I-he key 
to this strategy is the humble worm 
Cmzor%inlNi’itj,diti5 eIq~~tf.i. 
The wonders of worms 
Johnson says that. with worms. he can 
make a thought experiment a reality. 
“\Yhat ~OLI want to do is to mutate a 
million people with Alzhcimer’s 
disease and look for those in \vhom 
the dementia goes away. Then the 
mutated gent is your drug target. 
Alternatively. ~OLI would like to gi\,e 
100.000 different chemicals to humans 
with Alzheimer’s and see which one 
\\.orks. \Yc try to reconstruct the 
human disease in nematodes and then 
do the screens in nematodes.” 
‘I’hc advantages of C: ~~egil-ns are 
Icgion: They are small (a g-cm- 
diameter plate can support the growth 
of 100,000 animals), fast-growing (in 
licluid culture the doubling time is as 
little as eight hours), and they can be 
frozen for storage. Their biology and 
behavior is well characterized, with 
the interconnections of all neurons 
catalogued, and the exact sequence of 
cell divisions from embryo to adult 
known. There is a good physical map 
of the genomc, the genome sequence 
Lvill be completed later this year, and 
the self-fertilization of the 
hermaphroditic worms makes both 
dominant and recessive genetics 
relatively simple. “Genetics in the 
end is the correlation bet\veen 
genotype and phenotype, so having 
all thcsc tools on both sides is vcr\ 
powerful,” says Geoffrey Duyk, (:hief 
Scientific Officer of Exelixis, Inc. 
(South San Francisco, California). 
Exelixis uses 6’. &~LXLS and a host of 
other model organisms to look for ne\l 
components of disease-related 
pathways (see CLwn. Rid. 4. 703). 
Knockout technologies 
One thing lacking from the worm 
toolbox has been a method for making 
gene knockouts. In the solution 
de\ised by NemaPharm and others, 
mutated wwms are divided into pools, 
and genomic DNA har\.ested from 
each pool is added to a separate PCR 
reaction. The gene of interest is 
amplified. Reaction conditions are 
such that a shorter reaction product, 
from a copy of the gcnc nith a 
deletion. will be amplified many 
thousand-fold more efficiently. The 
store of live animals corresponding to 
the shorter PCR product is further 
subdivided until the individual clone 
Lvith the deletion in the gene of 
interest is identified. As Johnson say, 
“it is not exactly rocket science,” but 
it wwrks. Although some details of the 
method are proprietary the overall 
idea is not, and sytcmatic application 
to all (I: e/eyyz/z.s gents n-ill probably be 
taken on by a consortium of individual 
researchers, companies, and the 
Sanger Center in Cambridge, 
England. For now, NemaPharm has 
two full-time personnel. each 
generating one detction strain per 
week. Johnson belie\-es that a 
technological breakthrough to increase 
the speed of the method will bc 
Figure 1 
The ultimate worm dispenser. Image courtesy 
of NemaPharm. 
needed before it is reasonable to 
tackle the entire genomc. 
High speed worm sorting 
Knockouts are all \.ery well, but \vhat 
gets Johnson excited these days is 
high throughput phenotype analysis. 
“YOLI need an organism compatible 
~1 ith Y&well plates, and C. rlegow is, 
e\en \+ith 1.536-Lvel1 plates,” he says. 
“‘l’hat is an ad\ antage ~OLI won’t find 
in the other model animals.” 
“‘The first step is to get the 
chemicals into the Lvells, but the 
pharmaceutical industr>- has solved 
that problem,” hc says. “The next 
step is to get the \vorms into the 
wells.” The NcmaPharm \vorrn 
dispenser is modeled on a flop 
cyometer (Figure 1). Fast-moving 
fluid on the outside of the deliver)- 
cylinder straightens the \\‘orms out so 
a light-based detector can measure 
their length and thercforc their age. 
\Vorms of the appropriate age arc 
dispensed, filling a W-well plate in a 
couple of minutes. Johnson prides 
himself on his speed in manualI> 
transferring worms. Rut he says that, 
based on a head-to-head match-up 
with the machine. “I’\,e been made 
obsolete.” 
Picking your targets 
“6’. &~Q?I.s is a molecular tcchnolog):” 
say Johnson. “To do anything in 
C. e&~rzs VOLI need to know what 
molecules are inl,ol\.ed in the disease. 
Schizophrenia, for example, has no 
molecular handle on which to start.” 
R146 Chemistry & Biology 1996, Vol 5 No 6 
Johnson is interested in pathways: 
fleshing them out, switching them on 
and off, and working out which 
components are most amenable to 
drug inhibition. Not all pathways are 
appropriate targets. For a substrate- 
dependent pathway, says Johnson, “if 
you have something knocked out up- 
front there is nothing you can alter 
downstream to restore it. You need 
something like gene therapy.” The 
presenilin defect present in 
Alzheimer’s disease may fall into this 
category. “We looked at 
approximately one million mutated 
genomes. There are no genes that can 
be knocked out to suppress mutated 
presenilins. You’re not going to solve 
this by inhibiting another target.” 
(Both NemaPharm and Exelixis have, 
however, isolated suppressors of a 
partial loss of presenilin function.) 
“But in a switch pathway-the 
ras pathway, or apoptosis -the 
function of all the genes is reflected 
in whether the final part of the 
pathway is off or on,” says Johnson. 
Although the disease may have put a 
positive regulator out of commission, 
if Johnson can inhibit a negative 
regulator he may be able to turn the 
pathway back on. “We are looking for 
other things that we can knock out 
that will correct the disease,” he says. 
“It’s like two wrongs make a right.” 
Defining drug targets 
“This is really a target-identification 
technology not a drug-identification 
technology,” says Johnson. Where 
there are at most a few existing 
targets, such as with the presenilins, 
NemaPharm looks for new pathway 
components based on mutants that 
increase or decrease the severity of 
the original mutant phenotype. But if 
there are already many known 
components of a pathway, as is the 
case with ras, then NemaPharm uses a 
chemical screen to define the targets 
most readily inhibited by drugs. 
“Making a compound for a proof- 
of-concept in mammalian models is a 
lot of work,” says Johnson. In one 
step, a C. elegans screen selects a 
chemical inhibitor and a target that 
can be inhibited. More inhibitors can 
then be found by in vitro screens 
against the new target. 
Going from chemical to gene is 
difficult but not impossible. A 
mutant resistant to the chemical can 
be isolated. The mutant gene often 
encodes the drug’s target, and it can 
be mapped by standard methods. 
Death and depression 
One NemaPharm interest is 
apoptosis, or programmed cell death. 
Selectively blocking cell death could 
decrease damage in degenerative 
diseases or after strokes. The 
treatment will have to be local so that 
apoptosis can function in the disposal 
of virally infected and cancerous cells. 
The apoptosis screen uses ced9, 
the C. elegans homolog of human Bcl2. 
In the absence of ced9 function all C. 
elegans cells die. Mutations in other 
genes - such as ced3 and ced4, which 
encode components of the cell death 
machinery-will keep a ceti9 mutant 
animal alive. That can be detected 
automatically in a 96-well plate by 
measuring turbidity. Dead worms 
don’t eat their bacteria and the well 
water remains cloudy. But in the 
presence of either a ted? mutation or 
a chemical identified by 
NemaPharm, the ced9 worms eat up 
the bacteria and clear the water. 
Other phenotypes are not so easy 
to detect automatically. So far 
NemaPharm has relied on visual 
inspection to find suppressors of a 
dominant ras mutation (which causes 
extra vulvae to appear on the females) 
or to screen chemicals that, like the 
anti-depressant Prozac, inhibit 
serotonin re-uptake and so induce egg 
laying in the absence of food. “The 
way the read-outs are done now is 
quite biological and requires an 
expert,” says Johnson. “There has to 
be some easing of that requirement.” 
The company has several other 
interests, including proteins involved 
in pain control that are downstream 
of desensitization steps (so patients 
won’t get opiate-like resistance), and 
inhibitors of the secretion of immune 
modulators implicated in allergies. 
Just as egg laying is a good 
surrogate for anti-depressant action, 
for the newer targets any phenotype 
will do. “We are trying to use the 
same molecules and pathways in 
C. elegans, not to reproduce the same 
behaviors,” says Johnson. 
The test of the anti-depressants 
was used to confirm the accuracy of 
the C. elegans system, not as part of a 
search for new anti-depressants. The 
worm potency ranking actually 
outdid in vitro receptor-binding data 
as a predictor of potency in humans. 
This suggests that the worm system 
may mimic some in viva factors like 
bioavailability. The human digestive 
tract and the skin of C. elegans are 
both largely impermeable to charged 
chemicals, although the worm’s skin 
may exclude many more chemicals. 
The similarity of worm and human 
detoxification ability is also hard to 
predict. “I;: elegans has a tremendous 
potential to exclude chemicals,” says 
Johnson. NemaPharm is therefore 
deleting genes for many of the worm’s 
P-glycoproteins, the channels that 
pump foreign chemicals out of cells. 
Identifying the most important of the 
P450 detoxifying enzymes (there are 
-70 in all) is also a priority. 
Corporate takeover time 
In January 1998, Arris Pharmaceuticals 
Corporation (South San Francisco) 
bought Sequana Therapeutics (La 
Jolla, California), which just over a 
year earlier had bought NemaPharm. 
The new entity is called AXYS 
Pharmaceuticals, and NemaPharm 
will move to South San Francisco. 
Sequana uses genomics to find genes, 
NemaPharm prioritizes new targets, 
and Arris uses combinatorial chemistry 
to make chemicals for screening. 
“Now we have the full gene-to-drug 
spectrum in one company,” says 
Johnson, “and the chemicals are 
available without making deals. Over 
the next year, we are really going to 
start running screens.” 
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